For this purpose, we have quantified NF-κB1–DNA binding and nuclear RelA levels, as well as studied the expression of CGRP, SP, and TRPV1 both at the mRNA and protein levels in IVD tissues collected from DDD patients and postmortem (PM) controls. This evidence concerns the gene TFF2 and Dowling-Degos disease 1.